Abstract: The invention relates to a container (100) having an aperture (140) and a seal assembly (200), comprising a support member or disc (210) and a seal such as an induction seal (240). The support disc (210) has projections or cam surfaces (230) which engage with projections or cams (160) provided on the internal surface of the neck (120). The container is configured to have an intermediate configuration prior to containing a product, in which the container aperture is temporarily closed by the seal assembly (200). In this configuration, the internal cleanliness of the container is preserved. The seal assembly can be removed to add the product, and afterwards, the seal is made more permanent by applying induction energy to the seal and the container adopts a filled configuration containing the product in which the container aperture is sealed. In this configuration, the container may be sealed by the seal assembly (200) (i.e.

Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

Abstract: The present disclosure relates to improved cellular compositions and potency assays for obtaining the same. Such compositions and assays may be suitable for use in treating various inflammatory disorders.

Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

Abstract: The present disclosure relates to improved methods serum free stem cell culture, particularly 3D culture in bioreactors as well as cell culture medium and compositions for use in the same. Such methods may be particularly suitable for large scale cell manufacture.

Abstract: The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.

Abstract: An apparatus for separating cells from microcarriers comprises a chamber having a body and a base. The chamber is configured to receive a mixture comprising cells and microcarriers. The apparatus further comprises a filtration element disposed within the chamber and coupled to the body. The filtration element is configured to filter microcarriers from the mixture. The apparatus further comprises an adjustment mechanism coupled to the chamber. The adjustment mechanism is configured for selective extension and retraction of at least a portion of the body of the chamber to move the filtration element relative to the base of the chamber.

Abstract: The present disclosure relates to methods and compositions for expansion of human hematopoietic stem cells. The present disclosure also relates to methods of treatment involving the use of the expanded HSCs.

Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.

Abstract: The present disclosure relates to cellular therapy products comprising mesenchymal lineage precursor or stem cells and potency assay for these products. The present disclosure also relates to methods for treatment of immune or inflammatory disorders, and treatment or prevention of graft versus host disease (GVHD), or one or more symptoms associated with GVHD, by administration of mesenchymal lineage precursor or stem cells.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.

Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.

Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic application.